Privi speciality chemicals to merge subsidiaries for operational boost

On December 19, 2025, Privi Speciality Chemicals Limited (PSCL) approved a Scheme of Amalgamation to merge Privi Fine Sciences Private Limited (PFSPL) and Privi Biotechnologies Private Limited (PBPL) into PSCL. This strategic move aims to enhance operational efficiency, reduce costs, and maximize shareholder value by consolidating businesses with similar operations. The scheme is subject to approvals from shareholders, creditors, the National Company Law Tribunal, and other regulatory bodies.

The amalgamation will involve PSCL issuing one equity share of INR 10 for every 135 equity shares of PFSPL, while PBPL's shares held by PSCL will be cancelled. Post-merger, the promoter shareholding in PSCL will increase from 69.89% to 70.64%, and public shareholding will adjust from 30.11% to 29.36%, with total equity shares rising from 3,90,62,706 to 4,07,94,775.

This transaction is considered a related party transaction under SEBI LODR Regulations but is conducted at arm’s length, supported by valuation reports from RBSA Valuation Advisors LLP and a fairness opinion from Vivro Financial Services Private Limited. PFSPL and PBPL reported half-year turnovers of INR 3,147.14 Lakhs and INR 240.00 Lakhs, respectively, as of September 30, 2025, compared to PSCL’s INR 1,22,266.38 Lakhs.